Literature DB >> 25133047

Ischemic heart disease, factor predisposing to Barrett's adenocarcinoma: A case control study.

Panagiotis Tsibouris1, Mark T Hendrickse1, Panagiota Mavrogianni1, Peter Et Isaacs1.   

Abstract

AIM: To define the significance of ischemic heart disease (IHD) (stable angina to infarction) co-existance in Barrett esophagus (BE) patients and patients with esophageal adenocarcinoma (AdE).
METHODS: All BE/AdE patients in Blackpool-Wyre-Fylde area and Trikala prefecture identified from medical records. Patient clinical details were obtained from hospital and General Practitioner records. Additional information was gathered from validated questionnaire.
RESULTS: Forty (33%) AdE and 83 (19%) BE patients had IHD (P = 0.002). Eighteen (15%) AdE and 34 (8%) BE patients had suffered a myocardial infarction (P = 0.03). Three (3%) AdE and 7 (2%) BE patients had severe heart failure (P = 0.82). Thirty-nine (47%) BE with IHD and 8 (20%) AdE patients with IHD consumed aspirin daily (P = 0.004). Seventh-seven (93%) BE patients with IHD and 36 (90%) AdE patients with IHD were on statins (P = 0.86). Logistic regression analysis: AdE was more frequent in the elderly, with long term reflux, long BE and concurrent IHD (odds ratio: 2.086, P = 0.001) not consuming statins. Eighteen (22%) BE patients with IHD [16 (84%) with myocardial infarction] vs 33 (10%) without IHD died from non-neoplastic causes within 24 mo from BE diagnosis (P = 0.005).
CONCLUSION: IHD is more prevalent in AdE than BE patients. Increased prevalence of AdE is related with the presence of myocardial infarction but not severe heart failure, possibly because patients with BE and severe IHD have low life expectancy.

Entities:  

Keywords:  Barrett esophagus; Esophageal adenocarcinoma; Ischemic heart disease; Myocardial infarction; Non-steroidal anti-inflammatory drugs

Year:  2014        PMID: 25133047      PMCID: PMC4133444          DOI: 10.4292/wjgpt.v5.i3.183

Source DB:  PubMed          Journal:  World J Gastrointest Pharmacol Ther        ISSN: 2150-5349


  41 in total

1.  Letter to the editor regarding "Definition of Barrett's esophagus: time for a rethink-is intestinal metaplasia dead?".

Authors:  Steven R DeMeester
Journal:  Am J Gastroenterol       Date:  2010-05       Impact factor: 10.864

2.  Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus.

Authors:  Kenneth K Wang; Richard E Sampliner
Journal:  Am J Gastroenterol       Date:  2008-03       Impact factor: 10.864

3.  Endoscopic biopsy can detect high-grade dysplasia or early adenocarcinoma in Barrett's esophagus without grossly recognizable neoplastic lesions.

Authors:  B J Reid; W M Weinstein; K J Lewin; R C Haggitt; G VanDeventer; L DenBesten; C E Rubin
Journal:  Gastroenterology       Date:  1988-01       Impact factor: 22.682

Review 4.  Metabolic flexibility and cell hierarchy in metastatic cancer.

Authors:  Michael V Berridge; Patries M Herst; An S Tan
Journal:  Mitochondrion       Date:  2010-08-10       Impact factor: 4.160

5.  Nonsteroidal anti-inflammatory drugs and statins have chemopreventative effects in patients with Barrett's esophagus.

Authors:  Florine Kastelein; Manon C W Spaander; Katharina Biermann; Ewout W Steyerberg; Ernst J Kuipers; Marco J Bruno
Journal:  Gastroenterology       Date:  2011-08-28       Impact factor: 22.682

6.  Major predictors of long-term clinical outcomes after coronary revascularization in patients with unprotected left main coronary disease: analysis from the MAIN-COMPARE study.

Authors:  Sun-Yang Min; Duk-Woo Park; Sung-Cheol Yun; Young-Hak Kim; Jong-Young Lee; Soo-Jin Kang; Seung-Whan Lee; Cheol Whan Lee; Jae-Joong Kim; Seong-Wook Park; Seung-Jung Park
Journal:  Circ Cardiovasc Interv       Date:  2010-04       Impact factor: 6.546

7.  Early expression of angiogenesis factors in acute myocardial ischemia and infarction.

Authors:  S H Lee; P L Wolf; R Escudero; R Deutsch; S W Jamieson; P A Thistlethwaite
Journal:  N Engl J Med       Date:  2000-03-02       Impact factor: 91.245

8.  Effect of segment length on risk for neoplastic progression in patients with Barrett esophagus.

Authors:  R E Rudolph; T L Vaughan; B E Storer; R C Haggitt; P S Rabinovitch; D S Levine; B J Reid
Journal:  Ann Intern Med       Date:  2000-04-18       Impact factor: 25.391

9.  Mortality rates in patients with Barrett's oesophagus.

Authors:  P Moayyedi; N Burch; N Akhtar-Danesh; S K Enaganti; R Harrison; N J Talley; J Jankowski
Journal:  Aliment Pharmacol Ther       Date:  2007-12-06       Impact factor: 8.171

10.  Regular statin and aspirin use in patients with Barrett's oesophagus is associated with a reduced incidence of oesophageal adenocarcinoma.

Authors:  Ian L P Beales; Inna Vardi; Leanne Dearman
Journal:  Eur J Gastroenterol Hepatol       Date:  2012-08       Impact factor: 2.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.